BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 11762356)

  • 1. Circulating chromogranin A in the assessment of patients with neuroendocrine tumours. A single institution experience.
    Stivanello M; Berruti A; Torta M; Termine A; Tampellini M; Gorzegno G; Angeli A; Dogliotti L
    Ann Oncol; 2001; 12 Suppl 2():S73-7. PubMed ID: 11762356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical significance of blood chromogranin A measurement in neuroendocrine tumours.
    Seregni E; Ferrari L; Bajetta E; Martinetti A; Bombardieri E
    Ann Oncol; 2001; 12 Suppl 2():S69-72. PubMed ID: 11762355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Q RT-PCR detection of chromogranin A: a new standard in the identification of neuroendocrine tumor disease.
    Kidd M; Modlin IM; Mane SM; Camp RL; Shapiro MD
    Ann Surg; 2006 Feb; 243(2):273-80. PubMed ID: 16432362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of chromogranin A measurement in the work-up of neuroendocrine tumors.
    Baudin E; Bidart JM; Bachelot A; Ducreux M; Elias D; Ruffié P; Schlumberger M
    Ann Oncol; 2001; 12 Suppl 2():S79-82. PubMed ID: 11762357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones.
    Nobels FR; Kwekkeboom DJ; Coopmans W; Schoenmakers CH; Lindemans J; De Herder WW; Krenning EP; Bouillon R; Lamberts SW
    J Clin Endocrinol Metab; 1997 Aug; 82(8):2622-8. PubMed ID: 9253344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Somatostatin receptor scintigraphy versus chromogranin A assay in the management of patients with neuroendocrine tumors of different types: clinical role.
    Cimitan M; Buonadonna A; Cannizzaro R; Canzonieri V; Borsatti E; Ruffo R; De Apollonia L
    Ann Oncol; 2003 Jul; 14(7):1135-41. PubMed ID: 12853358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential clinical value of circulating chromogranin A in patients with prostate carcinoma.
    Berruti A; Dogliotti L; Mosca A; Gorzegno G; Bollito E; Mari M; Tarabuzzi R; Poggio M; Torta M; Fontana D; Angeli A
    Ann Oncol; 2001; 12 Suppl 2():S153-7. PubMed ID: 11762344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuroendocrine differentiation in carcinomas of the prostate: do neuroendocrine serum markers reflect immunohistochemical findings?
    Angelsen A; Syversen U; Haugen OA; Stridsberg M; Mjølnerød OK; Waldum HL
    Prostate; 1997 Jan; 30(1):1-6. PubMed ID: 9018329
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between neuroendocrine features and prognostic parameters in human prostate adenocarcinoma.
    Bollito E; Berruti A; Bellina M; Mosca A; Leonardo E; Tarabuzzi R; Cappia S; Ari MM; Tampellini M; Fontana D; Gubetta L; Angeli A; Dogliotti L
    Ann Oncol; 2001; 12 Suppl 2():S159-64. PubMed ID: 11762345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blood Chromogranin A Is Not Effective as a Biomarker for Diagnosis or Management of Bronchopulmonary Neuroendocrine Tumors/Neoplasms.
    Matar S; Malczewska A; Oberg K; Bodei L; Aslanian H; Lewczuk-Myślicka A; Filosso PL; Suarez AL; Kolasińska-Ćwikła A; Roffinella M; Kos-Kudła B; Ćwikła JB; Drozdov IA; Kidd M; Modlin IM
    Neuroendocrinology; 2020; 110(3-4):185-197. PubMed ID: 30995665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chromogranin A: its clinical value as marker of neuroendocrine tumours.
    Nobels FR; Kwekkeboom DJ; Bouillon R; Lamberts SW
    Eur J Clin Invest; 1998 Jun; 28(6):431-40. PubMed ID: 9693933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Processing-independent quantitation of chromogranin a in plasma from patients with neuroendocrine tumors and small-cell lung carcinomas.
    Børglum T; Rehfeld JF; Drivsholm LB; Hilsted L
    Clin Chem; 2007 Mar; 53(3):438-46. PubMed ID: 17259235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic value of plasma chromogranin A in neuroendocrine tumours.
    Tomassetti P; Migliori M; Simoni P; Casadei R; De Iasio R; Corinaldesi R; Gullo L
    Eur J Gastroenterol Hepatol; 2001 Jan; 13(1):55-8. PubMed ID: 11204811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Lanreotide Depot/Autogel on Urinary 5-Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors.
    Pavel ME; Phan AT; Wolin EM; Mirakhur B; Liyanage N; Pitman Lowenthal S; Fisher GA; Vinik AI;
    Oncologist; 2019 Apr; 24(4):463-474. PubMed ID: 30355775
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective Evaluation of the NETest as a Liquid Biopsy for Gastroenteropancreatic and Bronchopulmonary Neuroendocrine Tumors: An ENETS Center of Excellence Experience.
    Malczewska A; Witkowska M; Wójcik-Giertuga M; Kuśnierz K; Bocian A; Walter A; Rydel M; Robek A; Pierzchała S; Malczewska M; Leś-Zielińska I; Czyżewski D; Ziora D; Pilch-Kowalczyk J; Zajęcki W; Kos-Kudła B
    Neuroendocrinology; 2021; 111(4):304-319. PubMed ID: 32335553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Significance of plasma chromogranin A determination in neuroendocrine tumour (NET) diagnosis.
    Donica H; Malecha-Jędraszek A; Strosławska E; Burska A; Szubstarski F
    Folia Histochem Cytobiol; 2010 Dec; 48(4):603-10. PubMed ID: 21478104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours.
    Baudin E; Gigliotti A; Ducreux M; Ropers J; Comoy E; Sabourin JC; Bidart JM; Cailleux AF; Bonacci R; Ruffié P; Schlumberger M
    Br J Cancer; 1998 Oct; 78(8):1102-7. PubMed ID: 9792158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical significance of elevated serum chromogranin A levels.
    Syversen U; Ramstad H; Gamme K; Qvigstad G; Falkmer S; Waldum HL
    Scand J Gastroenterol; 2004 Oct; 39(10):969-73. PubMed ID: 15513336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma chromogranin A in patients with sporadic gastro-entero-pancreatic neuroendocrine tumors or multiple endocrine neoplasia type 1.
    Peracchi M; Conte D; Gebbia C; Penati C; Pizzinelli S; Arosio M; Corbetta S; Spada A
    Eur J Endocrinol; 2003 Jan; 148(1):39-43. PubMed ID: 12534356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum chromogranin A in the diagnosis and follow-up of neuroendocrine tumors of the gastroenteropancreatic tract.
    Schürmann G; Raeth U; Wiedenmann B; Buhr H; Herfarth C
    World J Surg; 1992; 16(4):697-701; discussion 701-2. PubMed ID: 1413839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.